收费全文 | 20723篇 |
免费 | 504篇 |
国内免费 | 158篇 |
耳鼻咽喉 | 60篇 |
儿科学 | 1078篇 |
妇产科学 | 763篇 |
基础医学 | 2676篇 |
口腔科学 | 203篇 |
临床医学 | 1070篇 |
内科学 | 5585篇 |
皮肤病学 | 326篇 |
神经病学 | 1678篇 |
特种医学 | 651篇 |
外国民族医学 | 1篇 |
外科学 | 3458篇 |
综合类 | 609篇 |
预防医学 | 756篇 |
眼科学 | 311篇 |
药学 | 1104篇 |
2篇 | |
中国医学 | 271篇 |
肿瘤学 | 783篇 |
2024年 | 19篇 |
2023年 | 107篇 |
2022年 | 246篇 |
2021年 | 340篇 |
2020年 | 223篇 |
2019年 | 1406篇 |
2018年 | 1337篇 |
2017年 | 608篇 |
2016年 | 204篇 |
2015年 | 259篇 |
2014年 | 403篇 |
2013年 | 382篇 |
2012年 | 358篇 |
2011年 | 396篇 |
2010年 | 286篇 |
2009年 | 276篇 |
2008年 | 278篇 |
2007年 | 265篇 |
2006年 | 258篇 |
2005年 | 216篇 |
2004年 | 210篇 |
2003年 | 188篇 |
2002年 | 153篇 |
2001年 | 132篇 |
2000年 | 101篇 |
1999年 | 96篇 |
1998年 | 75篇 |
1997年 | 77篇 |
1996年 | 60篇 |
1995年 | 46篇 |
1994年 | 47篇 |
1993年 | 31篇 |
1992年 | 25篇 |
1991年 | 37篇 |
1990年 | 27篇 |
1989年 | 20篇 |
1987年 | 24篇 |
1985年 | 1033篇 |
1984年 | 1767篇 |
1983年 | 1128篇 |
1982年 | 1213篇 |
1981年 | 1184篇 |
1980年 | 981篇 |
1979年 | 885篇 |
1978年 | 819篇 |
1977年 | 691篇 |
1976年 | 790篇 |
1975年 | 555篇 |
1974年 | 495篇 |
1973年 | 558篇 |
Purpose
To investigate the expression of IL-11 and its receptor IL-11Rα and to quantify density of CD163+ M2 macrophages in proliferative diabetic retinopathy (PDR). 相似文献Background
The purpose of the study was to evaluate the association between fetal echocardiographic measurements and the need for intervention (primary coarctation repair, staged coarctation repair, or catheter intervention) in prenatally diagnosed coarctation of the aorta.Methods
A single-centre retrospective cohort study (2005-2015) of 107 fetuses diagnosed with suspected coarctation of the aorta in the setting of an apex-forming left ventricle and antegrade flow across the mitral and aortic valves.Results
Median gestational age at diagnosis was 32 weeks (interquartile range, 23-35 weeks). Fifty-six (52%) did not require any neonatal intervention, 51 patients (48%) underwent a biventricular repair. In univariable analysis, an increase in ascending aorta (AAo) peak Doppler flow velocity (odds ratio [OR], 1.40 [95% confidence interval [CI], 1.05-1.91] per 20 cm/s; P = 0.03) was associated with intervention. No intervention was associated with larger isthmus size (OR, 0.23; P < 0.001), transverse arch diameter (OR, 0.23; P < 0.001), and aortic (OR, 0.72; P = 0.02), mitral (OR, 0.58; P = 0.001), and AAo (OR, 0.53; P < 0.001) z-scores. In multivariable analysis, higher peak AAo Doppler (OR, 2.51 [95% CI, 1.54-4.58] per 20 cm/s; P = 0.001) and younger gestational age at diagnosis (OR, 0.81 [95% CI, 0.70-0.93] per week; P = 0.005) were associated with intervention, whereas a higher AAo z-score (OR, 0.65 [95% CI, 0.43-0.94] per z; P = 0.029) and transverse arch dimension (OR, 0.44 [95% CI, 0.18-0.97]; P = 0.05) decreased the risk of intervention.Conclusions
In prenatally suspected coarctation, the variables associated with intervention comprised smaller AAo and transverse arch size, earlier gestational age at diagnosis, and the additional finding of a higher peak AAo Doppler. 相似文献Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献The results of lipid and lipoprotein cholesterol determinations showed decreases in serum total lipids, phospholipids, triglycerides and total cholesterol associated with similar decreases in HDL-, LDL- and VLDL-cholesterol fractions after NET-Ac.-treatment in monkeys. These effects were observed from week 4 onwards and maintained their magnitude up to week 12 after treatment. Since both HDL- and LDL-cholesterol fractions decreased, the HDL/LDL-ratio remained almost unchanged. Thus, the results obtained in this study after high-dose treatment with NET-Ac. in monkeys did not indicate any changes of lipid and lipoprotein parameters which in humans are supposed to be associated with an increased risk of cardiovascular lesions, namely a decrease in HDL- and increase in LDL-cholesterol fractions.
The results of blood coagulation and fibrinolytic parameters showed increased antithrombin-III and plasminogen levels besides minor changes in other parameters, thus indicating that NET-Ac. -treatment does not contribute to an increased risk of cardiovascular thrombotic events in the cynomolgus monkey. 相似文献